Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

Vogel, Victor G.; Costantino, Joseph P.; Wickerham, D. Lawrence; Cronin, Walter M.; Cecchini, Reena S.; Atkins, James N.; Bevers, Therese B.; Fehrenbacher, Louis; Pajon, Eduardo R.; Wade, James L.; Robidoux, A; Margolese, Richard G.; James, Joan; Lippman, Scott M.; Runowicz, Carolyn D.; Ganz, Patricia A.; Reís, Steven E.; McCaskill‐Stevens, Worta; Ford, Lea Berrang; Jordan, V. Craig; Wolmark, Norman

doi:10.1097/01.ogx.0000238648.23538.42

Cited by 153 publications

(193 citation statements)

References 0 publications

Supporting

Mentioning

187

Contrasting

Unclassified

Order By: Relevance

“…The chemopreventive properties of tamoxifen and raloxifene have recently been confirmed despite the risk of endometrial carcinoma that is related to their SERM activity (43,44). These data raise new insights into the mechanism that makes SERMs effective in decreasing the risk of breast cancer.…”

Section: Discussionmentioning

confidence: 88%

Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism

Payré

Médina

Boubekeur

et al. 2008

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

The microsomal antiestrogen-binding site (AEBS) is a highaffinity membranous binding site for the antitumor drug tamoxifen that selectively binds diphenylmethane derivatives of tamoxifen such as PBPE and mediates their antiproliferative properties. The AEBS is a hetero-oligomeric complex consisting of 3B-hydroxysterol-# 8 -# 7 -isomerase and 3B-hydroxysterol-# 7 -reductase. High-affinity AEBS ligands inhibit these enzymes leading to the massive intracellular accumulation of zymostenol or 7-dehydrocholesterol (DHC), thus linking AEBS binding to the modulation of cholesterol metabolism and growth control. The aim of the present study was to gain more insight into the control of breast cancer cell growth by AEBS ligands. We report that PBPE and tamoxifen treatment induced differentiation in human breast adenocarcinoma cells MCF-7 as indicated by the arrest of cells in the G 0 -G 1 phase of the cell cycle, the increase in the cell volume, the accumulation and secretion of lipids, and a milk fat globule protein found in milk. These effects were observed with other AEBS ligands and with zymostenol and DHC. Vitamin E abrogates the induction of differentiation and reverses the control of cell growth produced by AEBS ligands, zymostenol, and DHC, showing the importance of the oxidative processes in this effect. AEBS ligands induced differentiation in estrogen receptor-negative mammary tumor cell lines SKBr-3 and MDA-MB-468 but with a lower efficiency than observed with MCF-7. Together, these data show that AEBS ligands exert an antiproliferative effect on mammary cancer cells by inducing cell differentiation and growth arrest and highlight the importance of cholesterol metabolism in these effects.

show abstract

Section: Discussionmentioning

confidence: 88%

Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism

Payré

Médina

Boubekeur

et al. 2008

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…Breast cancer surveillance via annual breast MRI and mammography 41,42 Discuss chemoprevention for breast cancer (tamoxifen or raloxifene) 43,44 Discuss chemoprevention for breast cancer (tamoxifen) 43 …”

Section: Breast Cancermentioning

confidence: 99%

Clinical utility of a Web-enabled risk-assessment and clinical decision support program

Orlando

Myers

et al. 2016

Genetics in Medicine

View full text Add to dashboard Cite

Purpose: Risk-stratified guidelines can improve quality of care and cost-effectiveness, but their uptake in primary care has been limited. MeTree, a Web-based, patient-facing risk-assessment and clinical decision support tool, is designed to facilitate uptake of risk-stratified guidelines. Methods:A hybrid implementation-effectiveness trial of three clinics (two intervention, one control). Participants: consentable nonadopted adults with upcoming appointments. Primary outcome: agreement between patient risk level and risk management for those meeting evidence-based criteria for increased-risk risk-management strategies (increased risk) and those who do not (average risk) before MeTree and after. Measures: chart abstraction was used to identify risk management related to colon, breast, and ovarian cancer, hereditary cancer, and thrombosis.Results: Participants = 488, female = 284 (58.2%), white = 411 (85.7%), mean age = 58.7 (SD = 12.3). Agreement between risk management and risk level for all conditions for each participant, except for colon cancer, which was limited to those <50 years of age, was (i) 1.1% (N = 2/174) for the increased-risk group before MeTree and 16.1% (N = 28/174) after and (ii) 99.2% (N = 2,125/2,142) for the average-risk group before MeTree and 99.5% (N = 2,131/2,142) after. Of those receiving increased-risk risk-management strategies at baseline, 10.5% (N = 2/19) met criteria for increased risk. After MeTree, 80.7% (N = 46/57) met criteria. Conclusion:MeTree integration into primary care can improve uptake of risk-stratified guidelines and potentially reduce "overuse" and "underuse" of increased-risk services.

show abstract

“…Both medications were found to decrease breast cancer risk by about 50%. 8 The eligibility criterion for this study was a Gail model 5-year predicted breast cancer risk of at least 1.66%. The Gail model takes into account age, age at menarche, number of first-degree family members (maternal side only) diagnosed with breast cancer, number of breast biopsies, age at first live birth, and history of atypical hyperplasia.…”

Section: Discussionmentioning

confidence: 99%

Clinical Pearls in Breast Disease

Pruthi

Bundrick

Litin

2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

Cited by 153 publications

References 0 publications

Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism

Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism

Clinical utility of a Web-enabled risk-assessment and clinical decision support program

Clinical Pearls in Breast Disease

Contact Info

Product

Resources

About